Simvastatin as a neuroprotective treatment for Parkinson's disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study

Camille B Carroll, Douglas Webb, Kara Nicola Stevens, Jane Vickery, Vicky Eyre, Susan Ball, Richard Wyse, Mike Webber, Andy Foggo, John Zajicek, Alan Whone, Siobhan Creanor, Camille B Carroll, Douglas Webb, Kara Nicola Stevens, Jane Vickery, Vicky Eyre, Susan Ball, Richard Wyse, Mike Webber, Andy Foggo, John Zajicek, Alan Whone, Siobhan Creanor

Abstract

Introduction: Parkinson's disease (PD) is a progressive neurodegenerative condition affecting approximately 185,000 people in the UK. No drug has been proven to slow disease progression. Epidemiological and pre-clinical data support simvastatin, a widely used cholesterol-lowering drug with a well-established safety profile, having neuroprotective properties. The aim of this study (Simvastatin as a neuroprotective treatment for PD (PD STAT)) is to determine whether simvastatin has the potential to slow PD progression. The study is part of the International Linked Clinical Trials initiative coordinated by The Cure Parkinson's Trust. This paper describes the protocol for the PD STAT study.

Methods and analysis: PD STAT is a double-blind, randomised, placebo-controlled, multi-centre, parallel group, futility trial in patients with PD of mild-moderate severity. 235 participants have been recruited and randomly allocated in a 1:1 ratio to receive either oral simvastatin or matched placebo. Treatment involves a 1-month low-dose phase (40 mg daily), followed by a 23-month high-dose phase (80 mg daily) and ends with a 2-month washout period. Participants are reviewed at clinic visits at 1 month, 6, 12, 18, 24 and 26 months post-baseline, with interim telephone follow-up to monitor for adverse events.The primary outcome is the change in the Movement Disorder Society Unified Parkinson's Disease Rating Scale part III motor subscale score in the practically defined OFF medication state (OFF state) between baseline and 24 months. Primary analysis will be on a modified intention to treat basis and will include only those participants who progress to the high-dose phase of the study.

Ethics and dissemination: The protocol has been approved by the North East-Newcastle and North Tyneside 2 Research Ethics Committee. The results will be disseminated via research articles in peer-reviewed journals and presentations at local, national and international scientific meetings, as well as disseminated via patient groups, websites and networks. A summary of the study findings will be posted to participants at the end of the study.

Trial registration: ISRCTN16108482 (prospectively registered); EudraCT 2015-000148-40; ClinicalTrials.gov NCT02787590; Pre-results.

Keywords: MDS-UPDRS; Parkinson’s disease; neuroprotective effect; randomised controlled futility study; statin.

Conflict of interest statement

Competing interests: RW is Director of Research and Development at The Cure Parkinson’s Trust.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Scheduled follow-up assessments.

References

    1. The incidence and prevalence of Parkinson's in the UK report, 2018. Available:
    1. Friedman B, Lahad A, Dresner Y, et al. . Long-Term statin use and the risk of Parkinson's disease. Am J Manag Care 2013;19:626–32.
    1. Undela K, Gudala K, Malla S, et al. . Statin use and risk of Parkinson’s disease: a meta-analysis of observational studies. J Neurol 2013;260:158–65. 10.1007/s00415-012-6606-3
    1. Roy A, Pahan K. Prospects of statins in Parkinson disease. Neuroscientist 2011;17:244–55. 10.1177/1073858410385006
    1. Carroll CB, Wyse RKH. Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson’s Disease: Rationale for Clinical Trial, and Current Progress. J Parkinsons Dis 2017;7:545–68. 10.3233/JPD-171203
    1. Ghosh A, Roy A, Matras J, et al. . Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci 2009;29:13543–56. 10.1523/JNEUROSCI.4144-09.2009
    1. Chataway J, Schuerer N, Alsanousi A, et al. . Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. The Lancet 2014;383:2213–21. 10.1016/S0140-6736(13)62242-4
    1. Brundin P, Barker RA, Conn PJ, et al. . Linked clinical trials-the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments. J Parkinsons Dis 2013;3:231–9.
    1. Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes 2013;6:390–9.
    1. HL L, Jin DM, Liu M, et al. . Long-Term efficacy and safety of statin treatment beyond six years: a meta-analysis of randomized controlled trials with extended follow-up. Pharmacol Res 2014;81:64–73.
    1. Lang AE, Melamed E, Poewe W, et al. . Trial designs used to study neuroprotective therapy in Parkinson's disease. Mov Disord 2013;28:86–95. 10.1002/mds.24997
    1. Schwid SR, Cutter GR. Futility studies: spending a little to save a lot. Neurology 2006;66:626–7. 10.1212/01.wnl.0000204644.81956.65
    1. Creanor S, Vickery J, Eyre V, et al. . Two-arm randomised futility trials: PD-stat - a futility trial of a potential neuroprotective treatment in people with Parkinson's disease. Trials 2015;16 10.1186/1745-6215-16-S2-P236
    1. Goetz CG, Tilley BC, Shaftman SR, et al. . Movement disorder Society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): scale presentation and Clinimetric testing results. Mov Disord. 2008;23:2129–70. 10.1002/mds.22340
    1. Chan A-W, Tetzlaff JM, Altman DG, et al. . Spirit 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 2013;158:200–7. 10.7326/0003-4819-158-3-201302050-00583
    1. Stacy M, Hauser R, Oertel W, et al. . End-of-dose wearing off in Parkinson disease: a 9-question survey assessment. Clin Neuropharmacol 2006;29:312–21.
    1. Excellence NIfHaC Cardiovascular disease: risk assessment and reduction, including lipid modification (NICE guideline CG181), 2014. Available:
    1. Peninsula clinical trials unit. Available:
    1. Aiman U, Najmi A, Khan RA. Statin induced diabetes and its clinical implications. J Pharmacol Pharmacother 2014;5:181–5. 10.4103/0976-500X.136097
    1. Crandall JP, Mather K, Rajpathak SN, et al. . Statin use and risk of developing diabetes: results from the diabetes prevention program. BMJ Open Diab Res Care 2017;5 10.1136/bmjdrc-2017-000438
    1. Cederberg H, Stančáková A, Yaluri N, et al. . Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia 2015;58:1109–17. 10.1007/s00125-015-3528-5
    1. WHO , 2011. Available:
    1. Shulman LM, Gruber-Baldini AL, Anderson KE, et al. . The clinically important difference on the unified Parkinson's disease rating scale. Arch Neurol 2010;67:64–70. 10.1001/archneurol.2009.295
    1. Tilley BC, Palesch YY, Kieburtz K, et al. . Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology 2006;66:628–33. 10.1212/01.wnl.0000201251.33253.fb
    1. Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. . Exenatide and the treatment of patients with Parkinson’s disease. J. Clin. Invest. 2013;123:2730–6. 10.1172/JCI68295
    1. RCaC T. Biostatistics in clinical trials. Wiley, 2001.
    1. Schulz KF, Altman DG, Moher D. Consort 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010;152:726 10.7326/0003-4819-152-11-201006010-00232
    1. Piaggio G, Elbourne DR, Altman DG, et al. . Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA 2012;308:2594–604.
    1. Calvert M, Blazeby J, Altman DG, et al. . Reporting of patient-reported outcomes in randomized trials: the CONSORT pro extension. JAMA 2013;309:814–22.
    1. Eldridge SM, Chan CL, Campbell MJ, et al. . Consort 2010 statement: extension to randomised pilot and feasibility trials. BMJ 2016;355.
    1. Ioannidis JPA, Evans SJW, Gøtzsche PC, et al. . Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004;141:781–8. 10.7326/0003-4819-141-10-200411160-00009

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever